GRP78 Selective Inhibitors From a Direct‐to‐Biology Strategy
Angewandte Chemie International Edition · 2026
DOI: 10.1002/anie.202523960 ↗Kurz gefasst
Fachartikel in der Zeitschrift Angewandte Chemie International Edition, 2026. Verfasst von Xiaoyi Zhu und 12 weiteren Autor:innen. Beteiligte Einrichtung: College of Medicine, Department of Pharmacology and Therapeutics, Center For Inflammation Science and Systems Medicine, The Herbert Wertheim UF Scrip…. Hauptthemen laut MEDLINE: Heat-Shock Proteins, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: NCI NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
Because cancer cells have heightened protein homeostasis (proteostasis) requirements, there is interest in targeting proteostasis machinery, including the 70 kDa heat shock proteins (HSP70s), as potential cancer therapeutics. However, studies have shown that the HSP70 family is differentially regulated across cancers, and global targeting may produce unwanted toxicities. For this reason, our lab has focused on isoform‐selective targeting of HSP70s, including the endoplasmic reticulum‐resident HSP70, GRP78 (HSPA5 or BiP). GRP78 is a central component of protein homeostasis in the secretory system and is the principal regulator of the unfolded protein response (UPR). Here, we report the use of a direct‐to‐biology (D2B) strategy to optimize a dipeptide‐based scaffold that binds selectively to GRP78, relative to the other canonical HSP70s. We show that our lead compound, 12 , potently and selectively inhibits GRP78, binds to the substrate binding pocket, kills A549 lung cancer cells in 2D (grown as a monolayer) and 3D (grown as spheroids) cultures, engages GRP78 in cells, and that GRP78 inhibition is responsible for the mode of action. This work represents the first GRP78‐selective inhibitor that inhibits substrate binding.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Medicine, Department of Pharmacology and Therapeutics, Center For Inflammation Science and Systems Medicine, The Herbert Wertheim UF Scripps Institute For Biomedical Innovation and Technology, University of F…
- Department of Molecular Medicine, Center For Inflammation Science and Systems Medicine, UF Scripps Institute For Biomedical Innovation and Technology, Jupiter, Florida, USA.
- Genetics Graduate Interdisciplinary Program, University of Arizona, Tucson, Arizona, USA.
- Division of Hematology and Oncology, Department of Medicine, College of Medicine, University of Florida, Gainesville, Florida, USA.
- Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale School of Medicine, New Haven, Connecticut, USA.
- Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut, USA.
ORCID-Profile: Eli Chapman
Förderung
- NCI NIH HHS
- National Cancer Institute
Zitieren
APA
Zhu, X., Trindl, C. A., Li, Q., Ye, H., Alexander, L., Huang, D., Wei, Y., Trieu, V., Stansfield, B. N., Ooi, A., Yang-Hartwich, Y., Zhang, D. D., & Chapman, E. (2026). GRP78 Selective Inhibitors From a Direct‐to‐Biology Strategy. Angewandte Chemie International Edition. https://doi.org/10.1002/anie.202523960
Vancouver
Zhu X, Trindl CA, Li Q, Ye H, Alexander L, Huang D, et al. GRP78 Selective Inhibitors From a Direct‐to‐Biology Strategy. Angewandte Chemie International Edition. 2026. doi:10.1002/anie.202523960
BibTeX
@article{Zhu2026,
author = {Zhu, Xiaoyi and Trindl, Carlee A and Li, Qiu and Ye, Haofeng and Alexander, Lewis and Huang, Dichun and Wei, Yongyi and Trieu, Vyana and Stansfield, Ben N and Ooi, Aikseng and Yang-Hartwich, Yang and Zhang, Donna D and Chapman, Eli},
title = {GRP78 Selective Inhibitors From a Direct‐to‐Biology Strategy},
journal = {Angewandte Chemie International Edition},
year = {2026},
doi = {10.1002/anie.202523960}
}
EUVIMED